Teva & Barr Get Super-Sized
Teva Stock Dives After Inking $1.5 Billion Deal For Inflammation Drug | Investor's Business Daily
Allergan sells generic drug unit to Israel's Teva for $40.5 billion - Los Angeles Times
Teva Launches First Generic to Blockbuster Cancer Med
Generic Copaxone launches in US - PMLiVE
Generic-drug maker Teva steals market share from Big Pharma - Aug. 5, 2009
FOCUS-Generic drugmakers Teva and Sandoz make major push to biosimilars | Technology
BioSpace on LinkedIn: Sanofi, Teva Ink Potential $1.5B Deal Aimed at Blockbuster IBD Drug |…
Teva plans to sell Irvine drug plant – Orange County Register
Teva's Stock Price Surge Against Its Predictable Woes
A determined FDA takes down Teva's blockbuster | Evaluate
Teva Pharmaceuticals: Value Play or Value Trap? | by Shivam Kollur | Medium
Teva bullish ahead of 2-step biosimilar attack on AbbVie's blockbuster Humira
Pharma giant Teva looks to steady ship with new CEO in coming weeks | The Times of Israel
Teva Pharmaceutical: Slow Road To A Higher Share Price (NYSE:TEVA) | Seeking Alpha
Teva's Blockbuster Drug Takes Another Generic Blow | Ctech
Teva Pharmaceutical's Sales Slump 18% - WSJ
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
 "Zydus faces stiff competition for blockbuster drug in US from Teva Pharma")
Zydus faces stiff competition for blockbuster drug in US from Teva Pharma
Teva's flagship drug Austedo scores new approval at the FDA
Teva files potential blockbuster migraine drug for FDA approval
Israel's Teva gives upbeat outlook as restructuring proceeds | The Seattle Times
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Teva Pharmaceuticals appoints Richard Francis CEO | HealthCare Middle East & Africa Magazine
Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
Teva hopes Sanofi collaboration will lead to blockbuster IBD drug | Reuters
